Presentation is loading. Please wait.

Presentation is loading. Please wait.

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368: 679-86.

Published byAndreas Bundgaard Modified over 6 years ago

Similar presentations

Presentation on theme: "Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368: 679-86."— Presentation transcript:

1 Relative risks of clinical events for primary and secondary prevention with selected drugs
Thomas A Gaziano, et al. Lancet 2006; 368:

2 Region-based costs of cardiovascular disease interventions
Thomas A Gaziano, et al. Lancet 2006; 368:

3 Lifetime risk of death from cardiovascular disease according to regimen strategies* for World Bank regions Thomas A Gaziano, et al. Lancet 2006; 368:

4 Lifetime costs and QALYs of strategies assessed in six World Bank regions
Thomas A Gaziano, et al. Lancet 2006; 368:

5 Incremental cost-effectiveness ratios ($/QALY) for treatment regimens compared with no treatment
Thomas A Gaziano, et al. Lancet 2006; 368:

Download ppt "Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368: 679-86."

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
Key messages Stephen S Lim, et al. Lancet 2007; 370: 2054-62.

Key messages Stephen S Lim, et al. Lancet 2007; 370:
Trial profile Fox K et al. Lancet 2008;372:807-16.

Trial profile Fox K et al. Lancet 2008;372:
Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.
HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.

HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.
Randomized, double-blind, multicenter, controlled trial.

Randomized, double-blind, multicenter, controlled trial.
Frank B. Hu et al N Engl J Med 2004; 351: 2694- 703 Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.
M Mohsen Ibrahim, MD CARDIOLOGY DEPARTMENT-CAIRO UNIVERSITY MINIMAL vs OPTIMAL MEDICAL CARE.

M Mohsen Ibrahim, MD CARDIOLOGY DEPARTMENT-CAIRO UNIVERSITY MINIMAL vs OPTIMAL MEDICAL CARE.
By Judith Graham heart-attacks/ The Deadly Threat of Silent Heart Attacks.

By Judith Graham heart-attacks/ The Deadly Threat of Silent Heart Attacks.
Lancet 373:1765-72, 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.

TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Innovations in Management of Cardiovascular Disease for Global Health

Innovations in Management of Cardiovascular Disease for Global Health
Cardiovascular Outcome Strategy Implications for Primary Care Westcliffe Medical Practice Shipley Westcliffe Cardiology Service Dr Matthew Fay Westcliffe.

Cardiovascular Outcome Strategy Implications for Primary Care Westcliffe Medical Practice Shipley Westcliffe Cardiology Service Dr Matthew Fay Westcliffe.
The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340-1349. ?

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.

Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.
Shalev V, et al. Arch Intern Med 2009; 169:260-268.

Shalev V, et al. Arch Intern Med 2009; 169:
Trial profile Prakash Deedwania, et al. Lancet 2006; 368: 919-28.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
Trial profile Mann JF et al. Lancet 2008;372:547-53.

Trial profile Mann JF et al. Lancet 2008;372:
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.

Similar presentations

Ads by Google